Tau Immunotherapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
[Tau](/proteins/tau) immunotherapies represent one of the most advanced disease-modifying approaches for tauopathies, targeting the pathological accumulation and spread of hyperphosphorylated [tau protein](/proteins/tau) in the brain. These therapies aim to reduce neurofibrillary tangle formation and slow the progression of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and other tauopathies. [@sims2023]
Mechanism of Action
Tau immunotherapies work through several mechanisms to clear pathological tau: [@mullard2024]
Passive Immunization
Anti-tau monoclonal antibodies bind extracellular tau aggregates
Promote Fc-mediated microglial clearance of toxic species
Block neuron-to-neuron propagation of tau pathology
May enter [neurons](/entities/neurons) via receptor-mediated endocytosis
Active Immunization
Tau vaccines stimulate endogenous antibody production
Target specific tau epitopes (phosphorylated, truncation, conformational)
Elicit antibodies against extracellular tau oligomers and fibrils
Long-lasting immunity with periodic boosters
Key Tau Epitopes Targeted
pSer396/pSer404 (PHF-tau epitopes)
pThr231 (early phosphorylation marker)
N-terminal fragments (e.g., aa 6-15, 15-25)
Mid-domain regions (e.g., aa 184-238)
C-terminal fragments (e.g., aa 368-378)
Clinical Candidates
Passive Immunotherapies (Anti-Tau Antibodies)
Active Immunotherapies (Tau Vaccines)
Disease-Specific Applications
Alzheimer's Disease
Lecanemab (Leqembi): Approved for early AD (MCI due to AD, mild AD dementia)
Donanemab: Approved for early AD (MCI, mild dementia)
Target patients with amyloid positivity (PET or CSF)
May benefit from tau PET positivity
Combination with amyloid-lowering therapies under study
Progressive Supranuclear Palsy (PSP)
Gosutromab: Targeted 4R tau pathology
Phase II TANGO trial in PSP patients
Showed reduced tau burden in secondary analyses
Biomarker: CSF tau, tau PET
Corticobasal Degeneration (CBD)
Similar approach to PSP (4R tau)
Fewer clinical trials due to disease rarity
Antibody approaches may need to address both neuronal and glial pathology
Other Tauopathies
Chronic Traumatic Encephalopathy (CTE): Active investigation
The study of Tau Immunotherapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Pathway Diagram
Mermaid diagram (expand to render)
References
[van Dyck CH, et al, "Lecanemab in Early Alzheimer's Disease." N Engl J Med (2023)](https://pubmed.ncbi.nlm.nih.gov/36449413/)
[Sims JR, et al, "Donanemab in Early Symptomatic Alzheimer Disease." JAMA (2023)](https://pubmed.ncbi.nlm.nih.gov/36780248/)
[Mullard A, "Tau immunotherapy approaches the clinic." Nat Rev Drug Discov (2024)](https://pubmed.ncbi.nlm.nih.gov/38789472/)
[Jeremic D, et al, "Tau-targeting immunotherapies for Alzheimer's disease." Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37993567/)
[Sigurdsson EM, "Tau immunotherapy: progress and challenges." Acta Neuropathol (2024)](https://pubmed.ncbi.nlm.nih.gov/37284901/)
[Novak P, et al, "AADvac1 active tau immunotherapy." Lancet Neurol (2021)](https://pubmed.ncbi.nlm.nih.gov/34216387/)
[Teng E, et al, "Gosutromab in PSP (TANGO)." Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37116523/)
[Bittner T, et al, "Tau PET and immunotherapy." Nat Rev Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38216645/)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate